Ocugen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 65
- Market Cap
- $382.8M
- Website
- http://www.ocugen.com
- Introduction
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Ocugen Secures $30 Million in Debt Funding
Ocugen, Inc. secured a $30 million credit facility from Avenue Venture Opportunities Fund, L.P., extending its cash runway into Q1 2026, to fund clinical development of gene therapies and prepare for regulatory submissions.
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials
Ocugen to host Clinical Showcase on Nov 12, 2024, focusing on updates from ongoing gene therapy trials for retinitis pigmentosa, geographic atrophy, and Stargardt disease, with presentations by key executives and study investigators, concluding with a patient panel.
Ocugen Clinical Showcase Highlighting Progress in Retinal
Ocugen to host Clinical Showcase on Nov 12, 2024, at Nasdaq MarketSite, focusing on updates from ongoing gene therapy trials for retinitis pigmentosa, geographic atrophy, and Stargardt disease, with presentations by key executives and study investigators.
Ocugen Gets Green Light to Move Onto Phase 2 Portion of Trial Evaluating Stargardt Gene
Ocugen's OCU410ST, an AAV vector-based gene therapy for Stargardt disease, received DSMB clearance to proceed to phase 2 of the GARDian trial after demonstrating safety in phase 1 with no serious adverse events. The therapy, delivering the RORA gene, aims to address a substantial unmet need for Stargardt patients. Ocugen is also developing OCU400 for retinitis pigmentosa, showing safety and efficacy in earlier trials.
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian
DSMB approves Phase 2 enrollment for OCU410ST GARDian trial, with high dose identified as maximum tolerated dose; no serious adverse events reported.
Ocugen advances to phase 2 in Stargardt disease trial
Ocugen, Inc. received DSMB approval to progress to Phase 2 in its Phase 1/2 clinical trial of OCU410ST for Stargardt disease. The trial, conducted at six U.S. retinal surgery centers, completed Phase 1 without serious adverse events. OCU410ST, a modifier gene therapy, aims to address the unmet need for Stargardt patients. Ocugen also raised $32.6 million, extended financial runway, and saw FDA lift hold on OCU200 trial. Maxim Group initiated coverage with a Buy rating.
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST
Ocugen's OCU410ST GARDian trial DSMB approved Phase 2 enrollment, confirming OCU410ST's safety and tolerability for Stargardt disease, with no serious adverse events reported and high dose determined as maximum tolerated dose.
Ocugen to Host Conference Call on Friday, November 8
Ocugen to host Q3 2024 financial results and business update conference call on Nov 8, 2024, at 8:30 a.m. ET. Dial-in numbers: (800) 715-9871 (U.S.), (646) 307-1963 (international). Conference ID: 9923172. Webcast available on Ocugen's investor site. Replay and archived webcast accessible for 45 days.
Noble Financial Sticks to Its Buy Rating for Tonix Pharma (TNXP)
Noble Financial's Robert LeBoyer reiterated a Buy rating on Tonix Pharma (TNXP) on Oct 11, setting a $1.50 price target. Tonix shares closed at $0.15. LeBoyer, with an average return of -9.4% and a 27.97% success rate, covers Healthcare stocks. Tonix has a Moderate Buy consensus with a $6.25 price target. The company, founded in 2007, focuses on developing treatments for psychiatric, pain, and addiction conditions.
© Copyright 2024. All Rights Reserved by MedPath